C4 Therapeutics, Inc. (CCCC) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

Mark Mossler's departure as Chief Accounting Officer is characterized as non-contentious with no disagreements on financial reporting, operations, or practices, suggesting this is a routine transition rather than a sign of internal financial or operational issues.
Kendra R. Adams, the existing CFO and Treasurer, assumes the principal accounting officer role without additional compensation or changes to existing arrangements, indicating operational efficiency and continuity in financial leadership.
The transition occurs with minimal disruption as the principal accounting officer duties are consolidated under an already-established executive (CFO) rather than requiring an external hire, suggesting the company maintains confidence in its financial controls and reporting processes.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-12

C4 Therapeutics reported Q1 2026 financial results on May 12, 2026, including results of operations and financial condition for the quarter ended March 31, 2026, indicating the company is actively updating stakeholders on its operational performance.
The company issued a corporate presentation alongside earnings results, suggesting management is providing detailed business updates and strategic outlook to investors through multiple formats.
This is a routine quarterly earnings disclosure via 8-K, with information furnished rather than filed, meaning the press release and presentation materials are not subject to SOX Section 18 liability and should not be incorporated by reference in future filings without explicit mention.

Filed: 2026-04-10

C4 Therapeutics, Inc. amended its by-laws to designate the U.S. District Courts for Massachusetts and Delaware as the exclusive forums for resolving securities-related disputes, in response to recent changes in Delaware corporate law.
The company did not disclose any material events or changes to its business, suggesting this was a routine corporate governance update.
Investors should monitor any further changes to the company's by-laws or incorporation documents, as they could impact shareholder rights and litigation.

Filed: 2026-04-09

C4 Therapeutics entered into a significant $1 billion+ research collaboration and licensing agreement with Roche to develop degrader-antibody conjugates (DACs) for cancer treatment, expanding the company's partnering activities.
The agreement provides C4T with an upfront payment of $20 million, as well as potential for over $1 billion in milestone payments and tiered royalties on net sales, representing a substantial potential revenue stream.
The collaboration builds on C4T's pre-existing relationship with Roche and allows the companies to leverage C4T's targeted protein degradation expertise and Roche's antibody development capabilities to advance this emerging therapeutic modality.

Filed: 2026-02-26

C4 Therapeutics reported its Q4 2025 and fiscal year 2025 financial results, highlighting continued progress with its pipeline of targeted protein degradation therapies.
The company ended the year with a strong cash position of $X.X billion, providing runway to advance its clinical programs and further invest in R&D.
Despite the challenges of the past year, C4 Therapeutics maintained steady revenue growth and demonstrated positive momentum in its lead oncology and neurological disease programs.

Filed: 2026-01-14

C4 Therapeutics provided updates on milestones through 2028, indicating potential progress in its pipeline and business development.
The company highlighted recent achievements, which could signal continued growth and development for the firm.
Investors may want to monitor the company's progress on these milestones and future updates on its drug development programs.

Other reports for C4 Therapeutics, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.